Tania Small, SVP, Head of Medical Affairs at Bristol Myers Squibb, shared a post on LinkedIn:
“Myeloma has come a long way – and innovation is exploding.
For the first time, a functional cure doesn’t feel out of reach. But getting there will require some of the hardest conversations we’ve ever had.
MRD is gaining real momentum as a regulatory endpoint.
Immune-based therapies are delivering responses we couldn’t have imagined a decade ago.
And as we head into American Society of Hematology, the pace of discovery feels different – faster, closer, more possible.
But beneath the excitement are the questions we all wrestle with:
· Are we sequencing therapies in a way that truly changes long-term outcomes?
· What does “hit hard early” really mean in a world of quads, bispecifics, CAR T and ADCs?
· How do we treat the heterogeneity of this disease not as a single entity, but as the evolving set of clones it really is? Will we finally reach a point where therapy is individualized to the biology in front of us, not the averages behind us?
· And how do we make sure these breakthroughs don’t widen the survival gap but finally close it?
That’s the heart of this DoctorRx Unscripted conversation with Drs. Paul Richardson, Joe Mikhael, and Mecide Gharib – cutting through the complexities and asking the provocative questions: What now? What’s new? And what’s next?
Real talk. With real experts. In real time.
If you’re stepping into ASH or caring for myeloma patients every day, this one’s for you. And I’d love to hear how you’re thinking about these same questions.
To watch the full unscripted conversation, just search for DoctorRx Unscripted on the Bristol Myers Squibb website, YouTube, or wherever you listen to your podcasts.”
Proceed to the video attached to the post.
67th ASH Annual Meeting and Exposition
